Published in PLoS One on December 23, 2013
Retinoid roles in blocking hepatocellular carcinoma. Hepatobiliary Surg Nutr (2015) 0.75
Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice. Oncotarget (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab (2008) 18.87
Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology (2012) 10.00
Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell (2012) 9.88
Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer (2011) 9.68
A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell (2007) 9.20
The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science (2010) 6.38
Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med (1996) 6.01
Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov (2011) 5.79
The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist (2010) 4.68
Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51
Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer (2008) 3.39
Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res (1996) 3.36
Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology (2011) 3.24
Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation. Genes Dev (2011) 2.20
Cancer as a metabolic disease. Nutr Metab (Lond) (2010) 1.98
Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology (2013) 1.85
Metabolic pathway alterations that support cell proliferation. Cold Spring Harb Symp Quant Biol (2012) 1.83
Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathways. Gastroenterology (2005) 1.50
Depiction of metabolome changes in histidine-starved Escherichia coli by CE-TOFMS. Mol Biosyst (2007) 1.41
Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med (1999) 1.40
Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance. Cancer Res (2013) 1.19
Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res (2001) 1.16
Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development. Cancer Res (2012) 1.09
Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1. Cancer Res (2002) 1.03
Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis (2003) 1.02
Comprehensive mRNA expression profiling distinguishes tauopathies and identifies shared molecular pathways. PLoS One (2009) 0.96
(1)H-NMR-based metabolomics of tumor tissue for the metabolic characterization of rat hepatocellular carcinoma formation and metastasis. Tumour Biol (2010) 0.95
Integration of hepatitis B virus DNA into cells of six established human hepatocellular carcinoma cell lines. Hepatogastroenterology (1990) 0.92
Dual induction of caspase 3- and transglutaminase-dependent apoptosis by acyclic retinoid in hepatocellular carcinoma cells. Mol Cancer (2011) 0.90
Complex mixture analysis of organic compounds in green coffee bean extract by two-dimensional NMR spectroscopy. Magn Reson Chem (2010) 0.90
An acyclic retinoid, NIK-333, inhibits N-diethylnitrosamine-induced rat hepatocarcinogenesis through suppression of TGF-alpha expression and cell proliferation. Carcinogenesis (2004) 0.90
Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells. Hepatology (2002) 0.90
siRNA-mediated knockdown of aryl hydrocarbon receptor nuclear translocator 2 affects hypoxia-inducible factor-1 regulatory signaling and metabolism in human breast cancer cells. FEBS Lett (2011) 0.89
Evaluation of action mechanisms of toxic chemicals using JFCR39, a panel of human cancer cell lines. Mol Pharmacol (2007) 0.87
Prediction of metabolite identity from accurate mass, migration time prediction and isotopic pattern information in CE-TOFMS data. Electrophoresis (2010) 0.86
Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One (2012) 0.86
Acyclic retinoid inhibits angiogenesis by suppressing the MAPK pathway. Lab Invest (2009) 0.84
Mitochondria-targeted antioxidant and glycolysis inhibition: synergistic therapy in hepatocellular carcinoma. Anticancer Drugs (2013) 0.79
Effect of low-dose thalidomide on dopaminergic neuronal differentiation of human neural progenitor cells: a combined study of metabolomics and morphological analysis. Neurotoxicology (2012) 0.78
[Chemical evaluation by cancer cell line panel and its role in molecular target-based anticancer drug screening]. Gan To Kagaku Ryoho (2004) 0.77
[Results of molecular target antineoplastic agents screening]. Gan To Kagaku Ryoho (2004) 0.76
Branched-chain amino acids prevent hepatocarcinogenesis and prolong survival of patients with cirrhosis. Clin Gastroenterol Hepatol (2013) 0.90
Risk factors for pyrexia after endoscopic submucosal dissection of gastric lesions. Endosc Int Open (2014) 0.85
Revised criteria for classification of the etiologies of acute liver failure and late-onset hepatic failure in Japan: A report by the Intractable Hepato-biliary Diseases Study Group of Japan in 2015. Hepatol Res (2016) 0.78
Effect of zinc on liver cirrhosis with hyperammonemia: a preliminary randomized, placebo-controlled double-blind trial. Nutrition (2014) 0.77
The Use of Living Cancer Cells Expressing Green Fluorescent Protein in the Nucleus and Red Fluorescence Protein in the Cytoplasm for Real-time Confocal Imaging of Chromosome and Cytoplasmic Dynamics During Mitosis. Anticancer Res (2015) 0.76
Pharmaceutical and nutraceutical approaches for preventing liver carcinogenesis: chemoprevention of hepatocellular carcinoma using acyclic retinoid and branched-chain amino acids. Mol Nutr Food Res (2013) 0.76
Retinoid roles in blocking hepatocellular carcinoma. Hepatobiliary Surg Nutr (2015) 0.75
Antacid attenuates the laxative action of magnesia in cancer patients receiving opioid analgesic. J Pharm Pharmacol (2016) 0.75
Imaging Nuclear-Cytoplasmic Dynamics in Primary and Metastatic Colon Cancer in Nude Mice. Anticancer Res (2016) 0.75
Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice. Oncotarget (2017) 0.75
Non-alcoholic steatohepatitis-related liver tumorigenesis is suppressed in mice lacking hepatic retinoid storage. Oncotarget (2017) 0.75
Nationwide survey for acute liver failure and late-onset hepatic failure in Japan. J Gastroenterol (2017) 0.75